Detection of UGT1A1*28 gene polymorphisms by ligase chain reaction-PCR
LI Shuan-zuo1， LIU Ai-ning2， DU min3， LAI Jin-yun4， SONG Ming-xu5
(1. Health Team of Armed Police 8722 Troops, Wuxi Jiangsu 214062; 2. Department of Hematology, Affiliated Hospital of Jiangnan University, Wuxi Jiangsu 214062; 3. Department of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi Jiangsu 214062; 4. Library of the Affiliated Hospital of Jiangnan University,Wuxi Jiangsu 214062; 5. Oncology Institute, the Affiliated Hospital of Jiangnan University, Wuxi Jiangsu 214062, China)
Abstract：Objective: To establish a detection method of UGT1A1*28 gene polymorphisms based on ligase chain reaction and fluorescent PCR(LCRPCR) and to evaluate efficacy of its clinical application. Methods: LCRPCR primers and probes were designed to detect the UGT1A1*28 gene polymorphisms, constructed standard products to evaluate sensitivity and specificity of this method. Peripheral blood samples of 50 colorectal cancer patients were detected and compared with data obtained by DNA sequencing.Results: The LCRPCR technique could be used to detect the TA6/6,TA7/7 and TA6/7 of UGT1A1*28 gene, the detection limit is 5 ng genome DNA, and the results of 50 clinical samples detected by this method were in full agreement with those of the DNA sequencing. Conclusion: LCRPCR method can accurately detect UGT1A1*28 gene polymorphisms.
收稿日期: 2017-12-21
基金资助:
无锡市医院管理中心资助项目（YGZXQ1303）
通讯作者:
宋明旭（通讯作者），副主任检验技师，E-mail:songmingxu@126.com
作者简介: 李拴祚（1977—），男，主治医师
引用本文:
李拴祚1， 刘爱宁2， 杜敏3， 来锦云4， 宋明旭5. 连接酶链反应结合荧光PCR法检测UGT1A1*28基因多态性[J]. 江苏大学学报:医学版, 2018, 28(04): 302-306.
LI Shuan-zuo1， LIU Ai-ning2， DU min3， LAI Jin-yun4， SONG Ming-xu5. Detection of UGT1A1*28 gene polymorphisms by ligase chain reaction-PCR. Journal of Jiangsu University(Medicine Edition), 2018, 28(04): 302-306.
［1］Fujita K, Kubota Y, Ishida H, et al. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer\[J\]. World J Gastroenterol, 2015, 21(43):12234-12248.［2］Wulaningsih W, Wardhana A, Watkins J, et al. Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progressionfree survival in patients with advanced and/or metastatic colorectal cancer\[J\]. Cochrane Database Syst Rev, 2016,2:CD008593.［3］Marangon E, Posocco B, Mazzega E, et al. Development and validation of a highperformance liquid chromatographytandem mass spectrometry method for the simultaneous determination of irinotecan and its main metabolites in human plasma and its application in a clinical pharmacokinetic study\[J\]. PLoS One, 2015, 10(2):e0118194.［4］Fujiwara Y, Minami H. An overview of the recent progress in irinotecan pharmacogenetics\[J\]. Pharmacogenomics, 2010, 11(3):391-406.［5］Swami U, Goel S, Mani S. Therapeutic targeting of CPT11 induced diarrhea: a case for prophylaxis\[J\]. Curr Drug Targets, 2013, 14(7):777-797.［6］Iyer L，King CD，Whitington PF，et al. Genetic predisposition to the metabolism of irinotecan（CPT11）. Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite（SN38）in human liver microsomes［J］.J Clin Invest，1998, 101（4）：847-854.［7］Han JY, Lim HS, Shin ES, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with nonsmallcell lung cancer treated with irinotecan and cisplatin\[J\]. J Clin Oncol, 2006, 24(15):2237-2244.［8］Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDPglucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan\[J\]. J Clin Oncol, 2004, 22(8):1382-1388.［9］Minami H, Sai K, Saeki M, et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28\[J\]. Pharmacogenet Genomics, 2007, 17(7):497-504.［10］Jannin A, Hennart B, Adenis A, et al. Lifethreatening irinotecaninduced toxicity in an adult patient with alveolar rhabdomyosarcoma: the role of a UGT1A1 polymorphism\[J\].Case Rep Oncol Med, 2017, 2017：2683478.［11］MartinezBalibrea E , Abad A，MartinezCardus A ,et a1．UGT1A1 and TYM S genetic variants predict toxicity and response of colorectal cancer patients treated with firstline irinotecan and fluorouracil combination therapy\[J\]．Br J Cancer,2010,103(4):581-589.［12］Okuyama Y, Hazama S, Nozawa H, et al. Prospective phase Ⅱ study of FOLFIR I for mCRC in Japan, including the analysis of UGT1A1*28/*6 polymorphisms\[J\]. Jpn J Clin Oncol, 2011, 41 (4):477-482.［13］Jemal A, Siegel R, Ward E, et al. Cancer statistics\[J\]. CA Cancer J Clin, 2010, 60(5):277-300.［14］GarciaCarbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins\[J\]. Clin Cancer Res, 2008, 8(3):641-661.［15］Ulukan H, Swaan PW, Camptothecins: a review of their chemotherapeutic potential\[J\]. Drugs, 2002, 62(14):2039-2057.［16］Wu X, Cokkinides V, Chen VW, et al. Associations of subsitespecific colorectal cancer incidence rates and stage of disease at diagnosis with countylevel poverty, by race and sex\[J\].Cancer,2006,107(5 Suppl):1121-1127.［17］Miners JO, McKinnon RA, Mackenzie PI. Genetic polymorphisms of UDPglucuronosyltransferases and their functional significance\[J\]. Toxicology, 2002,181-182: 453-456.［18］Toffoli G, Cecchin E, Corona G, et al. Pharmacogenetics of irinotecan\[J\]. Curr Med Chem Anticancer Agents, 2003, 3(3):225-237.［19］Beutler E, Gelbart T, Demina A. Racial variability in the UDPglucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?\[J\]. Proc Natl Acad Sci USA, 1998, 95(14):8170-8174.［20］Iyer L, Hall D, Das S, et al. Phenotypegenotype correlation of in vitro SN38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism\[J\]. Clin Pharmacol Ther, 1999, 65(5):576-582.［21］Lauri A,Castiglioni B, Morabito S, et al. A tool based on Ligation Detection ReactionUniversal Array(LDRUA) for the characterization of VTEC by identification of virulenceassociated and serogroupspecific genes\[J\]. Mol Cell Probes, 2011, 25(1):35-43.［22］Cariani A, Piano A, Consolandi C,et al. Detection and characterization of pathogenic vibrios in shellfish by a Ligation Detection ReactionUniversal Array approach\[J\]. Int J Food Microbiol,2012, 153(3):474-482.［23］Datta S, Chatterjee S,Veer V.Recent advances in molecular diagnostics of hepatitis B virus［J］. World J Gastroenterol, 2014, 20(40):14615-14625.
2018, Vol. 28 
